Bicocca Open Archive

Logo unimib boa
CORTINOVIS, DIEGO LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.146
EU - Europa 3.423
AS - Asia 1.754
SA - Sud America 13
AF - Africa 7
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 4
Totale 11.353
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.068
IT - Italia 741
IE - Irlanda 686
SG - Singapore 684
DE - Germania 534
RU - Federazione Russa 527
HK - Hong Kong 428
CN - Cina 379
SE - Svezia 365
UA - Ucraina 151
ID - Indonesia 134
GB - Regno Unito 116
FI - Finlandia 79
CA - Canada 77
AT - Austria 67
IN - India 41
DK - Danimarca 38
FR - Francia 34
NL - Olanda 28
TR - Turchia 24
BE - Belgio 23
JP - Giappone 20
VN - Vietnam 19
BR - Brasile 11
PL - Polonia 11
KR - Corea 7
CZ - Repubblica Ceca 6
IR - Iran 5
EU - Europa 4
TW - Taiwan 3
AU - Australia 2
CH - Svizzera 2
CL - Cile 2
GR - Grecia 2
JO - Giordania 2
MU - Mauritius 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BG - Bulgaria 1
ES - Italia 1
ET - Etiopia 1
GN - Guinea 1
HR - Croazia 1
HU - Ungheria 1
IQ - Iraq 1
LU - Lussemburgo 1
MD - Moldavia 1
NG - Nigeria 1
PR - Porto Rico 1
RO - Romania 1
SC - Seychelles 1
SI - Slovenia 1
ZA - Sudafrica 1
Totale 11.353
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.270
Dublin 665
Singapore 588
Fairfield 533
Hong Kong 424
Woodbridge 411
Frankfurt am Main 368
Chandler 360
Ashburn 315
Wilmington 302
New York 265
Houston 231
Seattle 212
Cambridge 208
Santa Clara 199
Milan 183
Jacksonville 168
Princeton 146
Jakarta 134
Dearborn 125
Shanghai 76
Lawrence 66
Vienna 64
Altamura 57
Nanjing 48
Boardman 45
San Diego 44
Helsinki 43
London 43
Turin 41
Beijing 33
Guangzhou 33
Rome 29
Toronto 26
Andover 25
Lachine 25
Brussels 23
Munich 16
Ottawa 16
Hebei 15
Tianjin 15
Assago 14
Dong Ket 14
Jinan 14
Los Angeles 14
Pune 14
Dallas 13
Falls Church 13
Chicago 12
Nanchang 12
Hangzhou 11
Moscow 11
Shenyang 11
Bergamo 10
Genoa 10
Norwalk 10
Bologna 9
Lappeenranta 9
Lissone 9
Monza 9
Tokyo 9
Amsterdam 8
Lodi 8
Edmonton 7
Fremont 7
Nuremberg 7
São Paulo 7
Zhengzhou 7
Bari 6
Bonndorf 6
Cesano Maderno 6
Changsha 6
Huizen 6
Kunming 6
Mountain View 6
Ningbo 6
Redmond 6
Torre Del Greco 6
Brno 5
Carate Brianza 5
Carignano 5
Como 5
Hefei 5
Lodz 5
Perugia 5
Phoenix 5
Segrate 5
Torino 5
Alessandria 4
Corsico 4
Dongguan 4
Groningen 4
Jiaxing 4
Naples 4
New Bedfont 4
Paris 4
Reston 4
Romola 4
Verona 4
Alcamo 3
Totale 8.326
Salva come PNG Salva come JPEG
Nome #
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma 328
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 257
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 253
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 239
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve 233
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 220
Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis 216
Indicators of guideline-concordant care in lung cancer defined with a modified Delphi method and piloted in a cohort of over 5,800 cases 216
The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience 208
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer 188
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 185
Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNoms study 180
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 180
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients 178
C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool 177
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 173
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study 169
The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT 169
Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy 168
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 165
Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients 161
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 158
Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial 158
RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer 158
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study 157
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 157
MR309/E-52862, a first-in-class sigma-1 receptor antagonist, in oxaliplatin-induced peripheral neuropathy. An exploratory Phase II clinical trial 154
Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study. 152
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients 148
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 147
Long-term course of oxaliplatin-induced polyneuropathy: a prospective two-year follow-up study 146
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 145
When progressive dysphagia could be related to an “old friend” – a case report 144
Metabolic parameters as biomarkers of response to immunotherapy and prognosis in non-small cell lung cancer (Nsclc): A real world experience 144
The significance of dorsal sural nerve recordings in early detecting oxaliplatin-induced peripheral neuropathy. 136
The Association between Vitamin D and Gut Microbiota: A Systematic Review of Human Studies 136
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 127
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review 123
Vitamin D supplementation and cancer mortality: Narrative review of observational studies and clinical trials 117
Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer 115
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients 115
Novel cytotoxic chemotherapies in small cell lung carcinoma 112
Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift 105
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 101
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 99
ALK determination: Liquid and tissue biopsy. Comparing techniques and effectiveness of alectinib in a controversial clinical case [Determinazione di ALK: Tra biopsia liquida e tissutale. Tecniche a confronto ed efficacia di alectinib in un caso clinico controverso] 91
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab 91
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 87
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 85
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 84
Focus on nivolumab in NSCLC 84
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 84
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 80
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer 79
Oxaliplatin doublets in non-small cell lung cancer: A literature review 77
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? 76
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study 75
Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis 74
Clinical treatment of cholangiocarcinoma: an updated comprehensive review 69
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer 69
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 68
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study 64
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients 64
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 62
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer 62
Isolated cardiac metastasis from squamous cell esophageal cancer 60
Efficacy and safety of vinorelbine-capecitabine oral metronomic combinaton in elderly metastatc breast cancer patents: VICTOR-1 study 59
Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: A literature review 56
What are the options for non-small-cell lung cancer patients post second-line therapy? 55
Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: Analysis of 318 patients 55
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer 55
Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus 54
Treatment patterns, clinical outcomes and healthcare costs of advanced non-small cell lung cancer: A real-world evaluation in Italy 54
Challenges in ALK inhibition of ALK-positive non-small-cell lung cancer: From ALK positivity detection to treatment strategies after relapse 53
Targeted therapies and immunotherapy in non-small-cell lung cancer 51
Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review 50
Economic assessment of NGS testing workflow for NSCLC in a healthcare setting 47
Overall and disease-free survival greater than 12 years in metastatic non-small cell lung cancer after linear accelerator-based stereotactic radiosurgery for solitary brain metastasis 47
VITAMIN D SUPPLEMENTATION MAY IMPROVE COVID-19 PROGNOSIS? EVIDENCE FROM A SYSTEMATIC REVIEW AND META-ANALYSIS 45
Harnessing DLL3 inhibition: From old promises to new therapeutic horizons 44
Sneaky Diagnosis of Pleural Malignant Mesothelioma in Thoracic Surgery: All That Glitters Is Not Gold 43
Interpretation of lung cancer study outcomes 42
Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres 40
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma 39
Integrated therapeutic strategies for anaplastic thyroid carcinoma 39
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer 38
Project R. Evolution for improving clinical research in Italy: challenges and strategies 38
Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma 36
A new race against lung cancer 35
Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer 34
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer 34
Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders 33
Pulmonary carcinoid tumours: indolent but not benign 33
RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center 33
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial 33
The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database 32
Comment on: "is there a role for Vitamin D in human reproduction?" 32
Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer 30
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer 30
Targeted Therapies in Early Stage NSCLC: Hype or Hope? 29
Totale 10.530
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.902
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.902
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.108 0 0 0 0 0 155 196 264 214 118 128 33
2020/20211.499 76 62 151 133 87 94 152 178 142 155 126 143
2021/20221.108 102 144 159 114 64 77 50 42 55 58 82 161
2022/20231.743 211 504 138 184 112 244 24 117 113 39 43 14
2023/20242.515 45 44 45 64 588 530 444 77 309 57 47 265
2024/20252.293 312 712 289 252 541 187 0 0 0 0 0 0
Totale 12.143